UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema

October 31, 2022

https://www.globenewswire.com/news-release/2022/10/31/2545052/0/en/UNITY-Biotechnology-to-Host-Program-Update-on-BEHOLD-the-Phase-2-Clinical-Trial-of-UBX1325-in-Patients-with-Diabetic-Macular-Edema.html

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY” or the “Company”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a program update to discuss its lead program in UBX1325 on Tuesday, November 1, 2022 at 5:00 a.m. ET/8:00 a.m. ET, with retinal expert and key opinion leader Arshad M. Khanani, M.D., M.A., FASRS, Director of Clinical Research at Sierra Eye Associates.

Read more at globenewswire.com

Related news for (UBX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.